VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 164 filers reported holding VERVE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 1.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $39,967 | -61.6% | 8,190 | +4.4% | 0.00% | – |
| Q1 2024 | $104,142 | -41.9% | 7,842 | -39.0% | 0.00% | -100.0% |
| Q4 2023 | $179,282 | +90.0% | 12,861 | +80.8% | 0.00% | – |
| Q3 2023 | $94,345 | -29.3% | 7,115 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $133,406 | +94.1% | 7,115 | +49.3% | 0.00% | – |
| Q1 2023 | $68,726 | -25.5% | 4,766 | 0.0% | 0.00% | – |
| Q4 2022 | $92,222 | -41.6% | 4,766 | +3.3% | 0.00% | -100.0% |
| Q3 2022 | $158,000 | +251.1% | 4,612 | +58.0% | 0.00% | – |
| Q2 2022 | $45,000 | -32.8% | 2,919 | 0.0% | 0.00% | – |
| Q1 2022 | $67,000 | – | 2,919 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $37,665,169 | 23.26% |
| Alphabet Inc. | 10,549,086 | $197,795,362 | 10.63% |
| Casdin Capital, LLC | 2,360,571 | $44,260,706 | 3.87% |
| MPM BioImpact LLC | 857,940 | $16,086,375 | 3.24% |
| Redmile Group, LLC | 1,061,960 | $19,911,750 | 0.76% |
| Novo Holdings A/S | 500,000 | $9,375,000 | 0.72% |
| ARK Investment Management | 5,150,851 | $96,578,455 | 0.64% |
| Avidity Partners Management LP | 878,600 | $16,473,750 | 0.58% |
| Nikko Asset Management Americas, Inc. | 2,185,857 | $40,941,102 | 0.43% |
| Cormorant Asset Management, LP | 350,000 | $6,562,500 | 0.37% |